Cipher Pharmaceuticals Inc (CPH) - Total Assets
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) holds total assets worth CA$153.39 Million CAD (≈ $110.96 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CPH cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cipher Pharmaceuticals Inc - Total Assets Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check Cipher Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Cipher Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cipher Pharmaceuticals Inc's total assets of CA$153.39 Million consist of 17.9% current assets and 82.1% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$7.49 Million | 4.8% |
| Accounts Receivable | CA$11.19 Million | 7.2% |
| Inventory | CA$8.18 Million | 5.2% |
| Property, Plant & Equipment | CA$569.00K | 0.4% |
| Intangible Assets | CA$71.88 Million | 46.0% |
| Goodwill | CA$17.42 Million | 11.2% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Cipher Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cipher Pharmaceuticals Inc's current assets represent 17.9% of total assets in 2025, a decrease from 76.3% in 2004.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2025, down from 46.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 46.0% of total assets.
Cipher Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cipher Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Cipher Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 2.28 | 2.42 |
| Quick Ratio | 0.85 | 1.97 | 2.29 |
| Cash Ratio | 0.00 | 1.25 | 0.00 |
| Working Capital | CA$5.13 Million | CA$22.56 Million | CA$14.27 Million |
Cipher Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cipher Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 1.91 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CA$156.22 Million |
| Market Capitalization | $297.74 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cipher Pharmaceuticals Inc's assets above their book value (1.91x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Cipher Pharmaceuticals Inc's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual total assets of Cipher Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$156.22 Million ≈ $113.01 Million |
-3.87% |
| 2024-12-31 | CA$162.51 Million ≈ $117.56 Million |
+88.90% |
| 2023-12-31 | CA$86.03 Million ≈ $62.23 Million |
+16.61% |
| 2022-12-31 | CA$73.78 Million ≈ $53.37 Million |
+42.84% |
| 2021-12-31 | CA$51.65 Million ≈ $37.36 Million |
+16.66% |
| 2020-12-31 | CA$44.28 Million ≈ $32.03 Million |
-4.69% |
| 2019-12-31 | CA$46.45 Million ≈ $33.60 Million |
-16.58% |
| 2018-12-31 | CA$55.69 Million ≈ $40.28 Million |
-11.79% |
| 2017-12-31 | CA$63.13 Million ≈ $45.67 Million |
-18.44% |
| 2016-12-31 | CA$77.41 Million ≈ $55.99 Million |
-29.40% |
| 2015-12-31 | CA$109.65 Million ≈ $79.32 Million |
+884.67% |
| 2014-12-31 | CA$11.14 Million ≈ $8.06 Million |
-78.66% |
| 2013-12-31 | CA$52.17 Million ≈ $37.74 Million |
+136.40% |
| 2012-12-31 | CA$22.07 Million ≈ $15.96 Million |
+53.71% |
| 2011-12-31 | CA$14.36 Million ≈ $10.39 Million |
-11.21% |
| 2010-12-31 | CA$16.17 Million ≈ $11.70 Million |
+14.23% |
| 2009-12-31 | CA$14.16 Million ≈ $10.24 Million |
+5.20% |
| 2008-12-31 | CA$13.46 Million ≈ $9.73 Million |
-28.80% |
| 2007-12-31 | CA$18.90 Million ≈ $13.67 Million |
-2.11% |
| 2006-12-31 | CA$19.31 Million ≈ $13.97 Million |
-12.78% |
| 2005-12-31 | CA$22.14 Million ≈ $16.02 Million |
-31.59% |
| 2004-12-31 | CA$32.36 Million ≈ $23.41 Million |
-- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more